ImmunityBio, Inc. - IBRX STOCK NEWS

ImmunityBio has been granted a patent (U.S. Patent 11,071,774) for its NANT Cancer Vaccine, enhancing its proprietary immunotherapy approach. This candidate aims to stimulate the immune system against cancers using natural killer and T-cell therapies and has been in clinical testing since 2017. The NANT Cancer Vaccine has been studied in over 100 patients across various cancers, with a Phase 2 trial (QUILT 88) focused on metastatic pancreatic cancer. The patent recognition reaffirms the innovative treatment strategy aimed at reducing chemotherapy toxicity while providing long-term immunity.

ImmunityBio (NASDAQ: IBRX) received authorization from the South Africa Health Products Regulatory Authority to initiate the Sisonke T-Cell Universal Boost trial, set to begin in Q3 2021. This Phase 1/2/3 study will assess the efficacy of the hAd5 Spike + Nucleocapsid vaccine as a booster for healthcare workers already vaccinated with an S-only vaccine. Preliminary Phase 1 results indicate a 10-fold increase in T cell response. The trial will also explore combined vaccination routes, highlighting an urgent need for a boost to protect against emerging COVID-19 variants.

ImmunityBio (NASDAQ: IBRX) and NantOmics announced a new pipeline for identifying neoepitopes and neoepitope-reactive T cells in cancer patients. This methodology aims to personalize immunotherapy by predicting mutated peptide sequences that trigger immune responses. Collaborative efforts with leading institutions have shown promise in previous trials, hinting at improved cancer treatment outcomes. ImmunityBio's approach integrates bioinformatics for neoepitope discovery, potentially enhancing vaccine and cell transfer therapies.

ImmunityBio (NASDAQ: IBRX) has received FDA authorization for a Phase 1b/2 study to assess the safety and efficacy of Anktiva (N-803) and PD-L1 t-haNK cells combined with Trodelvy in advanced triple-negative breast cancer (TNBC) patients. This study aims to evaluate if the combination can enhance Trodelvy's effectiveness in patients who haven't responded to previous treatments. The global incidence of breast cancer was 2.3 million last year, with TNBC being particularly aggressive and accounting for 10-15% of cases. The trial seeks to offer new hope to this patient group.

ImmunityBio (NASDAQ: IBRX) announced the initiation of its HIV clinical pipeline, featuring a study of Anktiva™ (N-803) aimed at controlling HIV after pausing antiretroviral therapy. Sponsored by the NIAID, this trial evaluates Anktiva alone or with broadly neutralizing antibodies (bNABs). A second Phase 2 study will assess Anktiva during acute HIV infection, conducted by the U.S. Military HIV Research Program. Anktiva has shown potential in reversing HIV latency and activating immune responses, presenting a promising avenue for treatment alternatives.

ImmunityBio announced two clinical trials in South Africa to evaluate its hAd5 T-cell-based COVID-19 vaccine. The first trial focuses on using the vaccine as a "Universal Boost" for healthcare workers already vaccinated. The second will assess safety and efficacy after prior COVID-19 infection. Key features include multiple administration methods potentially enhancing access and effectiveness. Preliminary studies in the U.S. show promise with a 10-fold increase in T cell response. Future phases will involve larger participant groups to confirm long-term immunity against variants.

ImmunityBio, Inc. (NASDAQ: IBRX) announced that Founder Dr. Patrick Soon-Shiong will present at the 2021 Jefferies Virtual Healthcare Conference from June 1-4. The presentation, scheduled for June 4 at 11:30 a.m. EDT, will cover updates on the company's infectious disease and oncology programs. Attendees can access a live video webcast via the ImmunityBio Investor Relations website. ImmunityBio is a clinical-stage company focused on immunotherapy, with over 40 clinical trials in various stages, including treatments for cancers and infectious diseases.

ImmunityBio, Inc. (NASDAQ: IBRX) announced a poster presentation on its interleukin-15 superagonist Anktiva® at the upcoming 2021 ASCO Annual Meeting. The Phase 2 study examines Anktiva in combination with checkpoint therapy for patients who relapsed from prior treatments. The study involved 140 participants, showing a 68% disease control rate (82 out of 121 evaluable) and favorable toxicity compared to traditional therapies. The data suggests potential long-term benefits in multiple cancers, marking a significant step towards a chemotherapy-free immunotherapy approach.

ImmunityBio has received FDA authorization for a Phase 1 study evaluating its m-ceNK™ platform combined with Anktiva (N-803) in patients with advanced solid tumors. This novel approach utilizes NK cells from patients, enhanced with cytokines, to target cancer effectively. The trial will involve two cohorts: one with newly diagnosed patients and another with those who have undergone at least two prior therapies. This innovative therapy aims to significantly impact the clinical landscape of solid tumors, which constitute a large share of cancer diagnoses in the U.S.